Publications - 'F'
Publications 526 - 550 de 1212
| Titre | DOI |
|---|---|
|
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers E. Angevin; N. Isambert; V. Trillet-Lenoir; B. You; J. Alexandre; G. Zalcman; P. Vielh; F. Farace; F. Valleix; T. Podoll; Y. Kuramochi; I. Miyashita; O. Hosono; N.H. Dang; K. Ohnuma; T. Yamada; Y. Kaneko; C. Morimoto 2017 |
10.1038/bjc.2017.62 |
|
First-in-human phase I administration of YS110, a monoclonal antibody directed against the CD26 immunostimulatory molecule in advanced cancer patients. E. Angevin; N. Isambert; V.N. Trillet-Lenoir; B. You; J. Alexandre; G. Zalcman; P. Viehl; F. Farace; F. Valleix; T. Podoll; Y. Kuramochi; I. Miyashita; O. Hosono; N.H. Dang; K. Ohnuma; T. Yamada; Y. Kaneko; C. Morimoto 2015 |
10.1200/jco.2015.33.15_suppl.2519 |
|
First-line (1-L) bevacizumab plus chemotherapy (Bev/CT) in colorectal cancer (CRC) patients with potentially resectable liver only (LM) or liver and lung metastases (LLM): KRAS mutation analysis of the non-interventional PICASSO study D. Malka; J.P. Metges; D. Elias; J. Bennouna; F. Bonnetain; L.M. Dourthe; M. Ben Abdelghani; A. Radji; P. Laplaige; P. Laurent; J. Telliez; S. Bakiri; M. Rivoire 2016 |
10.1093/annonc/mdw370.35 |
|
First-line and second-line systemic treatments of patients with metastatic cutaneous melanoma (without brain metastasis) : French national guidelines D. Cupissol; B. Sassolas; P. Combemale; P. Modiano; C. Bedane; S. Derrey; I. Dygai-Cochet; L. Lamant; V. Lubrano; X. Mirabel; A. Mourregot; M.E.Rouge Bugat; S. Siegrist; J. Thariat; O. Tiffet; G. Truc; L. Verdoni; V. Mazeau-Woynar; F. Planchamp; M.T. Leccia 2014 |
10.1007/s10269-013-2360-4 |
|
First-Line Chemotherapy for Metastatic Esophageal Squamous Cell Carcinoma: Clinico-Biological Predictors of Disease Control N. Kotecki; S. Hiret; P.L. Etienne; N. Penel; E. Tresch; E. Francois; M.Pierre Galais; M. Ben Abdelghani; P. Michel; L. Dahan; F. Ghiringelli; L. Bedenne; E. Samalin; G. Piessen; J. Bennouna; C. Peugniez; F.El Hajbi; S. Clisant; A. Kramar; C. Mariette; A. Adenis 2016 |
10.1159/000442947 |
|
First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin's lymphoma D. Ghez; C. Fortpied; N. Mounier; P. Carde; A. Perrot; H. Khaled; S. Amorim; S. Ramadan; F.L. Bras; M. Erlanson; C. Herbaux; J.P. Marolleau; E. Nicolas-Virelezier; O. Casasnovas; A. Stamatoullas-Bastard; C. Ferme; E.O.R.T.C.Cooperatin Grp; L.Y.S.A.Cooperatin Grp; N.L.G.Cooperatin Grp 2017 |
10.1038/bmt.2016.271 |
|
First-line medical treatment of high-grade epithelial ovarian cancer F. Selle; J. Alexandre; K. Prulhiere; E. Kalbacher; I. Ray-Coquard; A. Leary; G. GINECO 2021 |
|
|
First-line pertuzumab (P), trastuzumab (H), and taxane therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC): Interim safety results (N=704) from PERUSE T.Denis Bachelot; E. Ciruelos; T. Peretz-Yablonski; F. Puglisi; A. Schneeweiss; M. Campone; B.P. Coudert; B. Kaufman; A.M. Wardley; L. Bastiere-Truchot; U. Freudensprung; E. Restuccia; D. Miles 2014 |
10.1200/jco.2014.32.15_suppl.548 |
|
First-line ribociclib (RIB) plus letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses G.N. Hortobagyi; S. Paluch-Shimon; K. Petrakova; C. Villanueva; A. Chan; A. Nusch; Y.Sim Yap; L. Hart; A. Favret; N. Marschner; G.S. Sonke; H.Oma Ohnstad; C. Arteaga; F. Su; W. He; M.Kristine Miller; S.M. Stemmer 2018 |
10.1200/JCO.2018.36.15_suppl.1022 |
|
First-line ribociclib plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2 G.N. Hortobagyi; S. Stemmer; M. Campone; G.S. Sonke; C.L. Arteaga; S. Paluch-Shimon; K. Petrakova; C. Villanueva; A. Nusch; E.M. Grischke; A. Chan; E. Jakobsen; N. Marschner; L.L. Hart; E. Alba; H.O. Ohnstand; S. Blau; D.A. Yardley; N. Solovieff; F. Su; C. Germa; Y.S. Yap 2018 |
|
|
First-line ribociclib plus letrozole in HR+, HER2-ABC: Efficacy by baseline tumor markers M. Campone; N. Marschner; C. Villanueva; G.S. Sonke; E. Alba; E. Jakobsen; F. Su; W. He; C. Germa; F. Andre 2017 |
|
|
First-line ribociclib plus letrozole in HR+, HER2-ABC: Efficacy by baseline tumor markers M. Campone; N. Marschner; C. Villanueva; G.S. Sonke; E. Alba; E. Jakobsen; F. Su; W. He; C. Germa; F. Andre 2017 |
|
|
First-line ribociclib plus letrozole in patients with de novo HR+, HER2-advanced breast cancer (ABC): A subgroup analysis of the MONALEESA-2 trial J. O'Shaughnessy; K. Petrakova; G.S. Sonke; F. Andre; P. Conte; C.L. Arteaga; D.A. Cameron; L.L. Hart; C. Villanueva; E.H. Jakobsen; D. Lindquist; F. Souami; X. Li; C. Germa; S. Hirawatand; G.N. Hortobagyi 2017 |
10.1158/1538-7445.SABCS16-P4-22-05 |
|
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial P. Joly; M. Maho-Vaillant; C. Prost-Squarcioni; V. Hebert; E. Houivet; S. Calbo; F. Caillot; M.Laure Golinski; B. Labeille; C. Picard-Dahan; C. Paul; M.A. Richard; J.David Bouaziz; S. Duvert-Lehembre; P. Bernard; F. Caux; M. Alexandre; S. Ingen-Housz-Oro; P. Vabres; E. Delaporte; G. Quereux; A. Dupuy; S. Debarbieux; M. Avenel-Audran; M. D'Incan; C. Bedane; N. Beneton; D. Jullien; N. Dupin; L. Misery; L. Machet; M. Beylot-Barry; O. Dereure; B. Sassolas; T. Vermeulin; J. Benichou; P. Musette; F.Study Grp Autoimmune 2017 |
10.1016/S0140-6736(17)30070-3 |
|
First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients. M. Balsat; V. Alcazer; G. Etienne; G. Fossard; F. Huguet; M.G. Berger; E. Cayssials; A. Charbonnier; M. Escoffre-Barbe; H. Johnson-Ansah; V. Dubruille; L. Legros; L. Roy; A.Jacques Delmer; J.C. Ianotto; M. Gardembas; F. Larosa; S. Courby; S. Ame; S. Morisset; F.X. Mahon; D. Rea; F.Emmanuel Nicolini 2018 |
10.1182/blood-2018-99-113058 |
|
First-line therapy for chronic lymphocytic leukemia in patients older than 79 years is feasible and achieves good results: A FILO retrospective study G. Meunier; L. Ysebaert; P.Linh Nguyen-Thi; S. Lepretre; A. Quinquenel; J. Dupuis; R. Lemal; T. Aurran; C. Tomowiak; F. Cymbalista; M.Sarah Dilhuydy; A. Brion; P. Morel; B. Cazin; V. Leblond; G. Cartron; D. Re; M.Christine Bene; A.Sophie Michallet; P. Feugier 2017 |
10.1002/hon.2370 |
|
First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis V. Nerich; J. Chelly; P. Montcuquet; L. Chaigneau; C. Villanueva; F. Fiteni; N. Meneveau; S. Perrin; A. Voidey; T. Monnot; X. Pivot; S. Limat 2014 |
10.1177/1078155213508440 |
|
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG) A. Ravaud; S. Oudard; M. De Fromont; C. Chevreau; G. Gravis; S. Zanetta; C. Theodore; M. Jimenez; E. Sevin; B. Laguerre; F. Rolland; M. Ouali; S. Culine; B. Escudier 2015 |
10.1093/annonc/mdv149 |
|
First-Principles Calculations of Structural, Electronic and Optical Properties of Ternary Semiconductor Alloys ZAs (x) Sb1-x (Z = B, Al, Ga, In) S. Bounab; A. Bentabet; Y. Bouhadda; G. Belgoumri; N. Fenineche 2017 |
10.1007/s11664-017-5425-9 |
|
First-Principles Computed Rate Constant for the O + O-2 Isotopic Exchange Reaction Now Matches Experiment G. Guillon; P. Honvault; R. Kochanov; V. Tyuterev 2018 |
10.1021/acs.jpclett.8b00661 |
|
First-Principles Study of the Interaction between NO and Large Carbonaceous Clusters Modeling the Soot Surface C. Garcia-Fernandez; S. Picaud; M.T. Rayez; J.C. Rayez; J. Rubayo-Soneira 2014 |
10.1021/jp412217q |
|
First-principles study of the reaction mechanism governing the SNAr of the dimethylamine on 2-methoxy-5-nitrothiophenes A. Smaoui; K. Essalah; T. Boubaker; X. Assfeld; F. Picaud; B. Tangour 2020 |
10.1007/s00214-019-2519-x |
|
First-trimester exposure to valproic acid treatment in bipolar disorders: a prospective comparative study using the Terappel database H. Ottomani; A. Gouraud; A.P. Jonville-Bera; A. Dautriche; P. Carlier; E. Amar; T. Vial 2014 |
|
|
First-trimester exposure to valproic acid treatment in bipolar disorders: a prospective comparative study using the Terappel database H. Ottomani; A. Gouraud; A.P. Jonville-Bera; A. Dautriche; P. Carlier; E. Amar; T. Vial 2014 |
|
|
FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) S. Oudard; O. Sartor; L. Sengelov; G. Daugaard; F. Saad; S. Hansen; M. Hjelm-Eriksson; J. Jassem; A. Thiery-Vuillemin; O. Caffo; D. Castellano; P.N. Mainwaring; J. Bernard; L. Shen; M. Chadjaa; K. Fizazi 2016 |
10.1093/annonc/mdw372.5 |